Start of Phase IIa study in acute lung injury patients marks development milestone for Apeiron's rhACE2
22-Dec-2011 -
Apeiron announced the initiation of a phase IIa clinical study of rhACE2, in patients with Acute Lung Injury (ALI). The study, of which Apeiron´s licensee GSK is sponsor, will include subjects with a positive diagnosis of ALI, and will be conducted in the intensive care units of multiple ...
acute lung injury
acute respiratory disease syndrome
GSK
+1